Indian drugmaker Ranbaxy to pay record fine in the US

Indian laboratory researchers conduct tests at the Ranbaxy Laboratories in Bombay India's generic drugmakers are some of the world's biggest producers

Related Stories

India's top drugmaker Ranbaxy Laboratories is to pay a record fine in the US for lying to officials and selling badly made generic drugs.

Ranbaxy said its US subsidiary would pay a $500m (£327m) fine, the biggest handed down to a generic drugmaker.

Ranbaxy USA pleaded guilty to improper manufacturing, storing and testing of drugs, closing a year-long civil and criminal investigation into the matter.

It also admitted lying about how it tested drugs at two Indian factories.

The impure drugs produced by Ranbaxy included an antibiotic and epilepsy treatment. The drugs have not led to any reported health issues.

Ranbaxy has also set aside an additional $500m to cover costs in the event of further criminal or civil suits.

"While we are disappointed by the conduct of the past that led to this investigation, we strongly believe that settling this matter now is in the best interest of all of Ranbaxy's stakeholders," said Arun Sawhney, chief executive and managing director of Ranbaxy, in a statement.

The fine "does not materially impact our current financial situation or performance", he added.

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More India stories

RSS

Features

  • Two sphinxes guarding the entrance to the tombTomb mystery

    Secrets of ancient burial site keep Greeks guessing


  • The chequeBig gamble

    How does it feel to bet £900,000 on the Scottish referendum?


  • Tattooed person using tabletRogue ink

    People who lost their jobs because of their tattoos


  • Deepika PadukoneBeauty and a tweet

    Bollywood cleavage row shows India's 'crass' side


  • Relief sculpture of MithrasRoman puzzle

    How to put London's mysterious underground temple back together


BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.